Edition:
United Kingdom

Dare Bioscience Inc (DARE.OQ)

DARE.OQ on NASDAQ Stock Exchange Capital Market

1.32USD
23 Feb 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$1.32
Open
$1.33
Day's High
$1.33
Day's Low
$1.27
Volume
37,142
Avg. Vol
40,804
52-wk High
$35.70
52-wk Low
$1.27

Chart for

About

Dare Bioscience, Inc., formerly Cerulean Pharma Inc., is a healthcare company. The Company is focused on the development and commercialization of products in women’s reproductive health. Its lead product candidate is Ovaprene, a clinical stage, non-hormonal contraceptive ring. The Company is developing Ovaprene to provide... (more)
No analyst recommendations are available for .

Overall

Beta: 2.58
Market Cap(Mil.): $19.23
Shares Outstanding(Mil.): 6.05
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 83.93 16.60
EPS (TTM): -- -- --
ROI: -- 1.66 10.66
ROE: -- 2.58 14.30

BRIEF-Empery Asset Management Lp Reports 9.05 pct Passive Stake In Dare Bioscience As Of Feb 13

* EMPERY ASSET MANAGEMENT LP REPORTS 9.05 PERCENT PASSIVE STAKE IN DARE BIOSCIENCE INC AS OF FEB 13, 2018 - SEC FILING‍​ Source text - (http://bit.ly/2CC1wzx) Further company coverage:

21 Feb 2018

BRIEF-Daré Bioscience Announces Effective License, Collaboration Deal For Topical Sildenafil

* DARÉ BIOSCIENCE, INC. ANNOUNCES EFFECTIVE LICENSE AND COLLABORATION AGREEMENT FOR TOPICAL SILDENAFIL FOR FEMALE SEXUAL AROUSAL DISORDER

15 Feb 2018

BRIEF-Dare Bioscience Inc To Raise About $10.25 Mln

* DARÉ BIOSCIENCE, INC. TO RAISE APPROXIMATELY $10.25 MILLION

13 Feb 2018

BRIEF-Daré Bioscience Announces Proposed Public Offering Of Common Stock

* DARÉ BIOSCIENCE, INC. ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

13 Feb 2018

BRIEF-Daré Bioscience Enters Into Agreement To License SST-6007, A Potential Treatment For FSAD

* DARÉ BIOSCIENCE, INC. ENTERS INTO LICENSE AND COLLABORATION AGREEMENT FOR A PRODUCT WITH THE POTENTIAL TO RECEIVE THE FIRST FDA APPROVAL FOR FEMALE SEXUAL AROUSAL DISORDER

12 Feb 2018

BRIEF-Dare Bioscience Enters Into A License Agreement With Strategic Science And Technologies

* DARE BIOSCIENCE INC - ON FEB 11, 2018, CO ENTERED INTO A LICENSE AGREEMENT WITH STRATEGIC SCIENCE AND TECHNOLOGIES-D & STRATEGIC SCIENCE TECHNOLOGIES

12 Feb 2018

BRIEF-Dare Bioscience Says Entered Into Common Stock Sales Agreement

* DARE BIOSCIENCE SAYS ON JANUARY 4, 2018, CO ENTERED INTO COMMON STOCK SALES AGREEMENT - SEC FILING

04 Jan 2018

Earnings vs. Estimates